Interstitial lung disease in a patient with anti-eIF2B antibodies-positive systemic sclerosis: A case report and literature review

Respir Med Case Rep. 2024 Nov 22:52:102141. doi: 10.1016/j.rmcr.2024.102141. eCollection 2024.

Abstract

We report the case of a 76-year-old male patient with systemic sclerosis positive for anti-eukaryotic initiation factor 2B (eIF2B) antibodies. He presented to our hospital with dyspnea on exertion and, following a comprehensive physical examination, was diagnosed with interstitial lung disease associated with systemic sclerosis. Furthermore, systemic sclerosis was positive for the anti-eIF2B antibody. The presence of anti-eIF2B antibodies in systemic sclerosis is very rare, occurring in only 1-2.5 % of cases and seldom reported. Similar to our case, systemic sclerosis with positive anti-eIF2B antibodies has been reported to be more likely to be complicated by interstitial lung disease. Herein, we discuss our case in detail and summarize the previous findings.

Keywords: Interstitial lung disease; Systemic sclerosis; anti-eIF2B antibodies.

Publication types

  • Case Reports